Evidence map›Paper›PMID 35389189›Full record

ArticleBreast cancer research and treatment2022

Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.

Linda Ye, Dennis Rünger, Stephanie A Angarita, Joseph Hadaya, Jennifer L Baker, Minna K Lee, Carlie K Thompson, Deanna J Attai, Maggie L DiNome

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Linda YeDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Dennis RüngerStatistics Core, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Stephanie A AngaritaDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Joseph HadayaDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jennifer L BakerDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Minna K LeeDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlie K ThompsonDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Deanna J AttaiDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Maggie L DiNomeDepartment of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA. Maggie.dinome@duke.edu.ORCID http://orcid.org/0000-0002-1926-292X
University of California, Los Angeles · USDuke University · USMemorial Sloan Kettering Cancer Center · US

Funding

Southern California Clinical and Translational Science Institute UL1TR000124UCLA
6 · The paper itself

Abstract

introductionStudies support omission of axillary lymph node dissection (ALND) for patients with sentinel node-positive disease, with ALND recommended for patients who present with clinically positive nodes. Here, we evaluate patient and tumor characteristics and pathologic nodal stage of patients with estrogen receptor-positive (ER +) breast cancer who undergo ALND to determine if differences exist based on nodal presentation. MATERIALS AND

methodsRetrospective chart review from 2010 to 2019 defined three groups of patients with ER + breast cancer who underwent ALND for positive nodes: SLN + (positive node identified at SLN biopsy), cNUS (abnormal preoperative US and biopsy), and cNpalp (palpable adenopathy). Patients who received neoadjuvant chemotherapy or presented with axillary recurrence were excluded.

resultsOf 191 patients, 94 were SLN + , 40 were cNUS, and 57 were cNpalp. Patients with SLN + compared with cNpalp were younger (56 vs 64 years, p < 0.01), more often pre-menopausal (41% vs 14%, p < 0.01), and White (65% vs 39%, p = 0.01) with more tumors that were low-grade (36% vs 8%, p < 0.01). Rates of PR + (p = 0.16), levels of Ki67 expression (p = 0.07) and LVI (p = 0.06) did not differ significantly among groups. Of patients with SLN + disease, 64% had pN1 disease compared to 38% of cNUS (p = 0.1) and 40% of cNpalp (p = 0.01). On univariable analysis, tumor size (p = 0.01) and histology (p = 0.04) were significantly associated with pN1 disease, with size remaining an independent predictor on multivariable analysis (p = 0.02).

conclusionHistorically, higher risk features have been attributed to patients with clinically positive nodes precluding omission of ALND, but when restricting evaluation to patients with ER + breast cancer, only tumor size is associated with higher nodal stage.

Indexed as

Breast NeoplasmsAxillaFemaleHumansLymphatic MetastasisLymph Node ExcisionReceptors, EstrogenRetrospective StudiesSentinel Lymph Node BiopsyReceptors, EstrogenAxillary lymph node dissectionBreast cancerClinically node-positiveNodal stagePalpable adenopathySentinel node biopsy

Identifiers

PMID35389189
OpenAlexW4225944240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.